Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

otelixizumab 1Gelsolin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Cytokine Release Syndrome × Clear all
NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

BioAegis Therapeutics Inc.

Phase 2 Completed
64 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

GlaxoSmithKline

Phase 1/2 Completed
30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡